Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
|Articles|March 2, 2019
GEMÜ Valves
GEMÜ Valves is a leading world-wide manufacturer of valves, measurement, and control systems for the Pharmaceutical, Microelectronics, and Semiconductor, and Food and Beverage industries, as well as the Chemical, Mining, and Metal Extraction, and Water/Waste Water Treatment industries.
GEMÜ Valves is a leading world-wide manufacturer of valves, measurement, and control systems for the Pharmaceutical, Microelectronics, and Semiconductor, and Food and Beverage industries, as well as the Chemical, Mining, and Metal Extraction, and Water/Waste Water Treatment industries. GEMÜ is committed to the pursuit of quality and excellence in the development, production, and manufacturing of engineered diaphragm valves.
3800 Camp Creek Pkwy SW, Bldg 2600 Suite 120, Atlanta, GA 30331
info@gemu.com
tel. 678.553.3400
fax. 404.344.9350
INTERPHEX Booth Number: 2663
Related to this article
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.